US Clinicals® StrongBiotics™ for Femicare

Female Intimate Care Product

Strongbiotics™ for Femicare is specially developed to provide women with effective and dual action support for female initimate care. It help to supports urinary tract & vaginal health, balance microflora & pH level of feminine part as well as improve female hygiene. Each capsule contains multi-strain 20 billion CFU FemiBiome™ live bacteria that are beneficial for long-term intimate care protection. With the addition of cranberry extract and pomegranate extract, it further enhances urinary tract and vaginal health.

Protect Your Feminine Health with StrongBiotics™ for Femicare

Lactobacilli are the most frequently identified microorganisms in the healthy human vagina. When their levels are low or absent, it can lead to discomfort or an imbalance in vaginal health.

FemiBiome™ Achievements

How Does It Work?

Support urinary tract & vaginal health

How are We Different from Others?

INSTRUCTIONS

Direction of Use:
For adults, take 1 capsule daily. Consume after meals.

Storage: Store in a cool and dry place. Once protection seal is opened, keep refrigerated (best consumed within 2 months). Keep out of reach of children.

Precaution: If you are nursing or pregnant, taking medication or have a medical condition, you should consult your health care specialist prior to using this product.

Made in Singapore.

FAQ

How soon will I be able to see the results?

Results may vary among individuals; most could expect to see beneficial effects such as reduced discomfort in the female intimate area. You are advised to take StrongBiotics™ for Femicare consecutively for 3-6 months to achieve the best results.

Will the long-term consumption of StrongBiotics™ for Femicare result in any side effects?

No known side effect has been observed. All the ingredients are tested and approved to ensure safety, purity and efficacy. Therefore, it is safe for long-term consumption at the recommended dosage.

US Clinicals® Safety Assurance

By Family, For Family

The US Clinicals® safety pledge

Our Mission?

To share quality health products, from our family to yours!

Scientific Evidence

1. Vicariotto, F., Mogna, L., Piano, M.D. (2014). Effectiveness of the Two Microorganisms Lactobacillus fermentum LF15 and Lactobacillus plantarum LP01, Formulated in Slow-release Vaginal Tablets, in Women Affected by Bacterial Vaginosis. J Clin Gastroenterol, 48(1), 106-112.

2. De Seta, F., Parazzini, F., De Leo, R., Banco, R., Maso, G.P., Santo, D.D., Sartore, A., Stabile, G., Inglese, S., Tonon, M., Restaino, S. (2014). Lactobacillus plantarum P17630 for preventing Candida vaginitis recurrence: a retrospective comparative study. European Journal of Obstetrics & Gynecology and Reproductive Biology, 182, 136-139.

3. Ho, M., Chang, Y.Y., Chang, W.C., Lin, H.C., Wang, M.H., Lin, W.C., Chiu, T.H. (2016). Oral Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 to reduce Group B Streptococcus colonization in pregnant women: A randomized controlled trial. Taiwanese Journal of Obstetrics & Gynecology, 55, 515-518.

4. Genis, S., Bach, A., Fabregas, F., Aris, A. (2015). Potential of lactic acid bacteria at regulating Escherichia coli infection and inflammation of bovine endometrium. Theriogenology, 1-13.

5. Deng, Q., Odhiambo, J.F., Farooq, U., Lam, T., Dunn, S.M., Ametaj, B.N. (2015, April 28). Intravaginal Lactic Acid Bacteria Modulated Local and Systemic Immune Responses and Lowered the Incidence of Uterine Infections in Periparturient Dairy Cows. PLoS ONE, 10(4).

6. Rossi, A., Rossi, T., Bertini, M., Caccia, G. (2010). The use of Lactobacillus rhamnosus in the therapy of bacterial vaginosis. Evaluation of clinical efficacy in a population of 40 women treated for 24 months. Arch Gynecol Obstet, 281, 1065-1069.